The Scientist - Home

FDA chief warns that high drug attrition rate is pushing up the cost of drug development

suggests a bigger at-risk population

Generic antiretrovirals taken off prequalification list after CROs fail quality standards

'Father of gene therapy' is charged with child molestation

U-C Irvine scientist, administrator founded first human genome research center in Berkeley

2.4-billion peso center will focus on health problems of the Mexican population

As politicians cheer the 'success' of a controversial stem cell import law, scientists fume

Twenty-five young researchers granted up to 1.25 million euros in inaugural prize

Stringent guidelines for implementing a controversial law met with shock by scientists

Semiconductor workers take issue with chosen research group's former industry ties

After a long famine, and buoyed by the stock market's overall health over the past 18 months, investors are once again feasting on initial public offerings (IPOs). Prominent among them are biotech firms. The news is good for the cash-starved biotech companies, since they finally have a place to raise money. But the news is not as good for IPO investors, who are getting uncertain returns in the post-IPO aftermarket."Although the general markets have been choppy all year and are likely to remain s

Five years after the UK Biobank first won financial backing in principle from the Wellcome Trust and the Medical Research Council, it has just about reached the point where bricks and mortar are being added to grand ideas and cautious plans. (When was originally approved in 1999, the Biobank resembled the UK Population Biomedical Collection, which sounded more like something you could order from a curio shop at the Census Bureau than a repository for tissue samples.)So even as Biobank fever arou